Botswana
Tuberculosis profile
| High HIV burden |
Population  2013 2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.44 (0.29–0.64) 22 (14–31)
Mortality (HIV+TB only) 0.93 (0.69–1.2) 46 (34–59)
Prevalence  (includes HIV+TB) 7 (3.9–11) 348 (194–545)
Incidence  (includes HIV+TB) 8.4 (8–9.1) 414 (396–452)
Incidence (HIV+TB only) 5 (4.8–5.5) 247 (236–270)
Case detection, all forms (%) 82 (75–85)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.5 (1.5–3.5) 6.6 (2.4–11)
MDR-TB cases among notified pulmonary
TB cases
120 (70–160) 69 (25–110)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 2 414   459
Pulmonary, clinically diagnosed 2 228   456
Extrapulmonary 1 152   125
       
Total new and relapse 6 834    
Previously treated, excluding relapses 124    
Total cases notified 6 958    
Among 6 834 new and relapse cases:
556 (8%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 8 (<1%) 37 (3%) 62
Laboratory-confirmed RR-/MDR-TB cases     67
Patients started on MDR-TB treatment     99
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 321 (91)
HIV-positive TB patients 3 832 (61)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 536 (92)
HIV-positive TB patients on antiretroviral therapy (ART) 2 753 (72)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 76
Previously treated cases registered in 2012 63
HIV-positive TB cases, all types, registered in 2012 75
RR-/MDR-TB cases started on second-line treatment in 2011 70
XDR-TB cases started on second-line treatment in 2011 67
Laboratories 2013  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 2.5
Drug susceptibility testing (per 5 million population) 2.5
Sites performing Xpert MTB/RIF 31
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 24
% Funded domestically 65%
% Funded internationally 4%
% Unfunded 31%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-02 Data: www.who.int/tb/data